Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Century Therapeutics (IPSC) Current Leases (2022 - 2025)

Century Therapeutics (IPSC) has disclosed Current Leases for 4 consecutive years, with $4.9 million as the latest value for Q2 2025.

  • On a quarterly basis, Current Leases rose 33.61% to $4.9 million in Q2 2025 year-over-year; TTM through Jun 2025 was $4.9 million, a 33.61% increase, with the full-year FY2024 number at $4.9 million, up 221.88% from a year prior.
  • Current Leases was $4.9 million for Q2 2025 at Century Therapeutics, roughly flat from $4.9 million in the prior quarter.
  • In the past five years, Current Leases ranged from a high of $4.9 million in Q2 2025 to a low of $475000.0 in Q4 2022.
  • A 4-year average of $3.1 million and a median of $3.7 million in 2024 define the central range for Current Leases.
  • Peak YoY movement for Current Leases: skyrocketed 221.88% in 2024, then soared 33.61% in 2025.
  • Century Therapeutics' Current Leases stood at $475000.0 in 2022, then surged by 218.53% to $1.5 million in 2023, then surged by 221.88% to $4.9 million in 2024, then rose by 0.49% to $4.9 million in 2025.
  • Per Business Quant, the three most recent readings for IPSC's Current Leases are $4.9 million (Q2 2025), $4.9 million (Q1 2025), and $4.9 million (Q4 2024).